Page last updated: 2024-11-13

i-antigen

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

I-antigen: used as a marker for well-differentiated leukemia cells; carbohydrate structure of immunodominant epitope is Galbeta1-4GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-3R which is very similar to that of sialyl SSEA-1 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID73427349
CHEBI ID61610
MeSH IDM0211517

Synonyms (10)

Synonym
i-antigen
beta-d-galactosyl-(1->4)-n-acetyl-beta-d-glucosaminyl-(1->3)-beta-d-galactosyl-(1->4)-n-acetyl-beta-d-glucosaminyl-(1->3)-(1->3)-beta-d-galactosyl-(1->4)-beta-d-glucosyl-(1<->1')-ceramide
CHEBI:61610 ,
galbeta1-4glcnacbeta1-3galbeta1-4glcnacbeta1-3galbeta1-4glcbeta1-1cer
lacto-n-norhexaosylceramide
(gal)3 (glc)1 (glcnac)2 (cer)1
nlc6cer
EPITOPE ID:149545
beta-d-galp-(1->4)-beta-d-glcpnac-(1->3)-beta-d-galp-(1->4)-beta-d-glcpnac-(1->3)-beta-d-galp-(1->4)-beta-d-glcp-(1<->1')-cer
Q28529700
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (36)

TimeframeStudies, This Drug (%)All Drugs %
pre-199021 (58.33)18.7374
1990's3 (8.33)18.2507
2000's4 (11.11)29.6817
2010's7 (19.44)24.3611
2020's1 (2.78)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.87 (24.57)
Research Supply Index3.74 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index42.09 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (31.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (2.50%)5.53%
Reviews1 (2.50%)6.00%
Case Studies1 (2.50%)4.05%
Observational0 (0.00%)0.25%
Other37 (92.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]